.jpg "Ampliphi Biosciences (AMEX: APHB)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ampliphi Biosciences (AMEX: APHB) and TherapeuticsMD (NYSE MKT: TXMD) with bullish sentiments.
Ampliphi Biosciences (AMEX: APHB)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB) yesterday and set a price target of $6. The company’s shares closed yesterday at $1.20.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -10.3% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
TherapeuticsMD (NYSE MKT: TXMD)
Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) yesterday and set a price target of $26. The company’s shares closed yesterday at $7.38, close to its 52-week high of $7.40.
Tanner observed:
“: We reiterate our Overweight rating and $26 PT for TXMD stock. We view the recent FDA approval of Imvexxy as a major milestone that sets the company on a course to achieve long-term commercial viability. The investability of TXMD stock has increased considerably, in our opinion, as the approval should buttress confidence in management’s ability to develop drug products and because the current stock price does not fully reflect the value of Imvexxy, much less that of TX-001. With a launch anticipated in August, we view Street expectations for Imvexxy revenues in 2018 and 2019 as reasonable.”
According to TipRanks.com, Tanner is a 4-star analyst with an average return of 10.9% and a 57.1% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
Currently, the analyst consensus on TherapeuticsMD is Strong Buy and the average price target is $16.40, representing a 122.2% upside.
In a report issued on May 30, Oppenheimer also reiterated a Buy rating on the stock with a $12 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TXMD:
